Valganciclovir vs valaciclovir for the prevention of cytomegalovirus inclusion disorders in renal transplant recipients

Trial Profile

Valganciclovir vs valaciclovir for the prevention of cytomegalovirus inclusion disorders in renal transplant recipients

Completed
Phase of Trial: Phase II

Latest Information Update: 11 Sep 2013

At a glance

  • Drugs Valaciclovir (Primary) ; Valganciclovir
  • Indications Cytomegalic inclusion disorders
  • Focus Pharmacodynamics; Therapeutic Use
  • Most Recent Events

    • 11 Sep 2013 Results presented at the 16th Congress of the European Society for Organ Transplantation.
    • 23 Aug 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top